Contineum Therapeutics (Contineum Therapeutics) Ending Cash Position : $16.26 Mil (As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Ending Cash Position?

Contineum Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 was $16.26 Mil.

Contineum Therapeutics's quarterly Ending Cash Position increased from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($15.53 Mil) and increased from Dec. 2023 ($15.53 Mil) to Mar. 2024 ($16.26 Mil).

Contineum Therapeutics's annual Ending Cash Position increased from Dec. 2021 ($4.63 Mil) to Dec. 2022 ($5.57 Mil) and increased from Dec. 2022 ($5.57 Mil) to Dec. 2023 ($15.53 Mil).

Contineum Therapeutics Ending Cash Position Historical Data

The historical data trend for Contineum Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Ending Cash Position Chart

Contineum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Ending Cash Position

4.63

5.57

15.53

Contineum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial			5.57	9.06	-	15.53	16.26

Contineum Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Contineum Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	5.569	+	9.957
	=	15.53

Contineum Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	15.526	+	0.738
	=	16.26

Contineum Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Contineum Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Contineum Therapeutics (Contineum Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.contineum-tx.com

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics (Contineum Therapeutics) Headlines

From GuruFocus

Contineum Therapeutics Announces Pricing of Initial Public Offering

By GlobeNewswire • 04-05-2024